Financhill
Buy
53

NVRO Quote, Financials, Valuation and Earnings

Last price:
$5.81
Seasonality move :
-5.06%
Day range:
$5.79 - $5.81
52-week range:
$3.17 - $14.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.53x
P/B ratio:
0.96x
Volume:
1.6M
Avg. volume:
1.6M
1-year change:
-58.27%
Market cap:
$222.6M
Revenue:
$408.5M
EPS (TTM):
-$3.05

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NVRO
Nevro
$102.6M -$0.76 -9.49% -42.86% $6.53
AXGN
Axogen
$49.4M $0.04 17.91% -76% $25.00
ELMD
Electromed
$15.3M -- 13.91% -- $37.00
GMED
Globus Medical
$646.2M $0.75 6.09% 580.52% $98.69
MYO
Myomo
$9.9M -$0.02 147.75% -20% $8.85
STXS
Stereotaxis
$6.4M -$0.07 -0.07% -20.83% $4.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NVRO
Nevro
$5.80 $6.53 $222.6M -- $0.00 0% 0.53x
AXGN
Axogen
$17.27 $25.00 $765.8M -- $0.00 0% 4.08x
ELMD
Electromed
$24.62 $37.00 $210.7M 32.83x $0.00 0% 3.70x
GMED
Globus Medical
$71.04 $98.69 $9.8B 94.72x $0.00 0% 3.88x
MYO
Myomo
$5.19 $8.85 $178.4M -- $0.00 0% 6.02x
STXS
Stereotaxis
$1.83 $4.50 $156.1M -- $0.00 0% 5.79x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NVRO
Nevro
49.41% 0.537 160.36% 3.54x
AXGN
Axogen
31.37% 0.673 6.53% 1.88x
ELMD
Electromed
-- 1.614 -- 4.68x
GMED
Globus Medical
9.6% 2.915 3.9% 1.72x
MYO
Myomo
-- 2.236 -- 2.82x
STXS
Stereotaxis
-- 1.401 -- 0.74x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NVRO
Nevro
$65.9M -$23M -23.22% -42% -43.88% $16.6M
AXGN
Axogen
$37.6M $2M -6.89% -10.21% 4.56% $7.9M
ELMD
Electromed
$12.6M $2.5M 15.91% 15.91% 15.64% $2.9M
GMED
Globus Medical
$393.9M $77.1M 2.31% 2.56% 11.72% $193.2M
MYO
Myomo
$8.6M -$245.3K -48.64% -48.64% -2.03% $2.5M
STXS
Stereotaxis
$3.2M -$7.6M -139.2% -139.2% -120.3% -$4.3M

Nevro vs. Competitors

  • Which has Higher Returns NVRO or AXGN?

    Axogen has a net margin of -50.32% compared to Nevro's net margin of 0.91%. Nevro's return on equity of -42% beat Axogen's return on equity of -10.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVRO
    Nevro
    62.45% -$1.41 $456.6M
    AXGN
    Axogen
    76.06% $0.01 $151.4M
  • What do Analysts Say About NVRO or AXGN?

    Nevro has a consensus price target of $6.53, signalling upside risk potential of 12.64%. On the other hand Axogen has an analysts' consensus of $25.00 which suggests that it could grow by 44.76%. Given that Axogen has higher upside potential than Nevro, analysts believe Axogen is more attractive than Nevro.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVRO
    Nevro
    0 12 0
    AXGN
    Axogen
    4 0 0
  • Is NVRO or AXGN More Risky?

    Nevro has a beta of 0.943, which suggesting that the stock is 5.654% less volatile than S&P 500. In comparison Axogen has a beta of 1.024, suggesting its more volatile than the S&P 500 by 2.388%.

  • Which is a Better Dividend Stock NVRO or AXGN?

    Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NVRO or AXGN?

    Nevro quarterly revenues are $105.5M, which are larger than Axogen quarterly revenues of $49.4M. Nevro's net income of -$53.1M is lower than Axogen's net income of $450K. Notably, Nevro's price-to-earnings ratio is -- while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.53x versus 4.08x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVRO
    Nevro
    0.53x -- $105.5M -$53.1M
    AXGN
    Axogen
    4.08x -- $49.4M $450K
  • Which has Higher Returns NVRO or ELMD?

    Electromed has a net margin of -50.32% compared to Nevro's net margin of 12.11%. Nevro's return on equity of -42% beat Electromed's return on equity of 15.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVRO
    Nevro
    62.45% -$1.41 $456.6M
    ELMD
    Electromed
    77.68% $0.22 $43.6M
  • What do Analysts Say About NVRO or ELMD?

    Nevro has a consensus price target of $6.53, signalling upside risk potential of 12.64%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 50.28%. Given that Electromed has higher upside potential than Nevro, analysts believe Electromed is more attractive than Nevro.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVRO
    Nevro
    0 12 0
    ELMD
    Electromed
    2 0 0
  • Is NVRO or ELMD More Risky?

    Nevro has a beta of 0.943, which suggesting that the stock is 5.654% less volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

  • Which is a Better Dividend Stock NVRO or ELMD?

    Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NVRO or ELMD?

    Nevro quarterly revenues are $105.5M, which are larger than Electromed quarterly revenues of $16.3M. Nevro's net income of -$53.1M is lower than Electromed's net income of $2M. Notably, Nevro's price-to-earnings ratio is -- while Electromed's PE ratio is 32.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.53x versus 3.70x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVRO
    Nevro
    0.53x -- $105.5M -$53.1M
    ELMD
    Electromed
    3.70x 32.83x $16.3M $2M
  • Which has Higher Returns NVRO or GMED?

    Globus Medical has a net margin of -50.32% compared to Nevro's net margin of 4.03%. Nevro's return on equity of -42% beat Globus Medical's return on equity of 2.56%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVRO
    Nevro
    62.45% -$1.41 $456.6M
    GMED
    Globus Medical
    59.92% $0.19 $4.6B
  • What do Analysts Say About NVRO or GMED?

    Nevro has a consensus price target of $6.53, signalling upside risk potential of 12.64%. On the other hand Globus Medical has an analysts' consensus of $98.69 which suggests that it could grow by 38.93%. Given that Globus Medical has higher upside potential than Nevro, analysts believe Globus Medical is more attractive than Nevro.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVRO
    Nevro
    0 12 0
    GMED
    Globus Medical
    6 4 0
  • Is NVRO or GMED More Risky?

    Nevro has a beta of 0.943, which suggesting that the stock is 5.654% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.186, suggesting its more volatile than the S&P 500 by 18.608%.

  • Which is a Better Dividend Stock NVRO or GMED?

    Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NVRO or GMED?

    Nevro quarterly revenues are $105.5M, which are smaller than Globus Medical quarterly revenues of $657.3M. Nevro's net income of -$53.1M is lower than Globus Medical's net income of $26.5M. Notably, Nevro's price-to-earnings ratio is -- while Globus Medical's PE ratio is 94.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.53x versus 3.88x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVRO
    Nevro
    0.53x -- $105.5M -$53.1M
    GMED
    Globus Medical
    3.88x 94.72x $657.3M $26.5M
  • Which has Higher Returns NVRO or MYO?

    Myomo has a net margin of -50.32% compared to Nevro's net margin of -2.16%. Nevro's return on equity of -42% beat Myomo's return on equity of -48.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVRO
    Nevro
    62.45% -$1.41 $456.6M
    MYO
    Myomo
    71.39% -$0.01 $24.7M
  • What do Analysts Say About NVRO or MYO?

    Nevro has a consensus price target of $6.53, signalling upside risk potential of 12.64%. On the other hand Myomo has an analysts' consensus of $8.85 which suggests that it could grow by 70.52%. Given that Myomo has higher upside potential than Nevro, analysts believe Myomo is more attractive than Nevro.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVRO
    Nevro
    0 12 0
    MYO
    Myomo
    3 0 0
  • Is NVRO or MYO More Risky?

    Nevro has a beta of 0.943, which suggesting that the stock is 5.654% less volatile than S&P 500. In comparison Myomo has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.902%.

  • Which is a Better Dividend Stock NVRO or MYO?

    Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NVRO or MYO?

    Nevro quarterly revenues are $105.5M, which are larger than Myomo quarterly revenues of $12.1M. Nevro's net income of -$53.1M is lower than Myomo's net income of -$260.1K. Notably, Nevro's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.53x versus 6.02x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVRO
    Nevro
    0.53x -- $105.5M -$53.1M
    MYO
    Myomo
    6.02x -- $12.1M -$260.1K
  • Which has Higher Returns NVRO or STXS?

    Stereotaxis has a net margin of -50.32% compared to Nevro's net margin of -118.53%. Nevro's return on equity of -42% beat Stereotaxis's return on equity of -139.2%.

    Company Gross Margin Earnings Per Share Invested Capital
    NVRO
    Nevro
    62.45% -$1.41 $456.6M
    STXS
    Stereotaxis
    50.73% -$0.09 $11.4M
  • What do Analysts Say About NVRO or STXS?

    Nevro has a consensus price target of $6.53, signalling upside risk potential of 12.64%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 145.9%. Given that Stereotaxis has higher upside potential than Nevro, analysts believe Stereotaxis is more attractive than Nevro.

    Company Buy Ratings Hold Ratings Sell Ratings
    NVRO
    Nevro
    0 12 0
    STXS
    Stereotaxis
    2 0 0
  • Is NVRO or STXS More Risky?

    Nevro has a beta of 0.943, which suggesting that the stock is 5.654% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.546, suggesting its more volatile than the S&P 500 by 54.601%.

  • Which is a Better Dividend Stock NVRO or STXS?

    Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NVRO or STXS?

    Nevro quarterly revenues are $105.5M, which are larger than Stereotaxis quarterly revenues of $6.3M. Nevro's net income of -$53.1M is lower than Stereotaxis's net income of -$7.5M. Notably, Nevro's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.53x versus 5.79x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NVRO
    Nevro
    0.53x -- $105.5M -$53.1M
    STXS
    Stereotaxis
    5.79x -- $6.3M -$7.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock